<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408441</article-id><article-id pub-id-type="pmc">PMC12101741</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0324072</article-id><article-id pub-id-type="publisher-id">PONE-D-24-15103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Receptor Antagonist Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Receptor Antagonist Therapy</subject><subj-group><subject>Beta-Adrenergic Antagonist Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Myocardial Infarction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Statins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Cardiovascular Therapy</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Adherence to secondary preventive treatment following myocardial infarction with and without obstructive coronary artery disease</article-title><alt-title alt-title-type="running-head">Medical adherence in MINOCA and MI-CAD</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6531-1024</contrib-id><name><surname>Nordenskj&#x000f6;ld</surname><given-names>Anna M.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Qvarnstr&#x000f6;m</surname><given-names>Miriam</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0531-2516</contrib-id><name><surname>Wettermark</surname><given-names>Bj&#x000f6;rn</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lindahl</surname><given-names>Bertil</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Cardiology, Faculty of Medicine and Health, &#x000d6;rebro University, &#x000d6;rebro, Sweden</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Medical Sciences, Uppsala University, Uppsala, Sweden</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Truyen</surname><given-names>Thien Tan Tri Tai</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Tan Tao University, VIET NAM</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>anna.nordenskjold@regionorebrolan.se</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0324072</elocation-id><history><date date-type="received"><day>2</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Nordenskj&#x000f6;ld et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nordenskj&#x000f6;ld et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0324072.pdf">
</self-uri><abstract><sec id="sec001"><title>Background</title><p>Secondary preventive medications following myocardial infarction (MI) reduce the risk of new cardiovascular events. Discontinuation and suboptimal adherence are common and affect prognosis. However, there is limited knowledge regarding adherence in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA). We therefore aim to evaluate the adherence to guideline recommended medications in patients with MINOCA and myocardial infarction with obstructive coronary arteries (MI-CAD).</p></sec><sec id="sec002"><title>Methods</title><p>This was a Swedish nationwide observational study of MI patients recorded in the SWEDEHEART registry between 2006&#x02500;2017. A total of 9,138 MINOCA and 107,240 MI-CAD patients were followed for a mean 5.9 years. Initiation of therapy, implementation determined using medication possession ratio, and persistence rates during different time periods were calculated.</p></sec><sec id="sec003"><title>Results</title><p>Patients with MINOCA were less frequently prescribed secondary preventive medications than MI-CAD. The percentage of patients taking medication as prescribed were lower in MINOCA than in MI-CAD at all time points; during months 6&#x02500;12 after discharge: aspirin 94.8% vs 97.2% (p&#x02009;&#x0003c;&#x02009;0.001), statins 90.3% vs 94.7% (p&#x02009;&#x0003c;&#x02009;0.001), and ACEI/ARBs 97.7% vs 98.5% (p&#x02009;=&#x02009;0.002) and at 12 months: aspirin 84.4% vs 93.7% (p&#x02009;&#x0003c;&#x02009;0.001), statins 83.8% vs 94.8% (p&#x02009;&#x0003c;&#x02009;0.001), ACEI/ARBs 85.0% vs 92.2% (p&#x02009;&#x0003c;&#x02009;0.001) and beta blockers 80.4% vs 89.6% (p&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec id="sec004"><title>Conclusion</title><p>The rates of initiation, implementation, and persistence of secondary preventive medications were high in both MINOCA and MI-CAD patients during the first 5 years after MI. The lower rates in patients with MINOCA may be partially due to uncertainties regarding the diagnosis of MINOCA, differences in patient characteristics, and psychosocial factors. Suboptimal medical adherence in patients with MINOCA may adversely affect prognosis as previously demonstrated in MI-CAD patients.</p></sec></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100018367</institution-id><institution>Swedish Foundation for MS Research</institution></institution-wrap>
</funding-source><principal-award-recipient>
<name><surname>Lindahl</surname><given-names>Bertil</given-names></name>
</principal-award-recipient></award-group><funding-statement>Bertil Lindahl received a grant from the Swedish Foundation for Strategic Research that was used to support this study. The Swedish Foundation for Strategic Research had no role in the design of the study; the collection, management, analysis, and interpretation of the data; the preparation or review of the manuscript; or the decision to submit the manuscript for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="4"/><page-count count="18"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Due to Swedish laws on personal integrity and health data, as well as the Ethics Committee, we are not allowed to make any data included health variables open to the public even if made anonymous. The data could be shared with other researchers after a request to the head of the department of Medical Sciences, Uppsala University, Sweden. At present Josef J&#x000e4;rhult holds this position. Please use this general e-mail address to the institution: <email>prefekt@medsci.uu.se</email>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Due to Swedish laws on personal integrity and health data, as well as the Ethics Committee, we are not allowed to make any data included health variables open to the public even if made anonymous. The data could be shared with other researchers after a request to the head of the department of Medical Sciences, Uppsala University, Sweden. At present Josef J&#x000e4;rhult holds this position. Please use this general e-mail address to the institution: <email>prefekt@medsci.uu.se</email>.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Outcomes after acute myocardial infarction (MI) can be improved by lifestyle changes; control of cardiovascular risk factors; and treatment with secondary preventive medications, such as aspirin, P2Y12-inhibitors, statins, beta blockers, angiotensin-converting enzyme inhibitors (ACEIs), and/or angiotensin-receptor blockers (ARBs), all of which are recommended in international guidelines [<xref rid="pone.0324072.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0324072.ref003" ref-type="bibr">3</xref>].</p><p>Suboptimal treatment after MI has been repeatedly observed, with too few patients initiated on recommended secondary preventive treatments and many patients showing insufficient adherence to medication [<xref rid="pone.0324072.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0324072.ref013" ref-type="bibr">13</xref>]. Poor adherence to prescribed secondary preventive drugs has been found to adversely affect prognosis [<xref rid="pone.0324072.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0324072.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0324072.ref012" ref-type="bibr">12</xref>].</p><p>About 6&#x02013;8% of patients who experience MI are diagnosed with myocardial infarction with non-obstructive coronary arteries (MINOCA) [<xref rid="pone.0324072.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0324072.ref015" ref-type="bibr">15</xref>]. Although this disorder was first recognized in the early 1980&#x02019;s [<xref rid="pone.0324072.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0324072.ref018" ref-type="bibr">18</xref>], diagnostic criteria and treatment recommendations for MINOCA have only recently been established [<xref rid="pone.0324072.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0324072.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0324072.ref020" ref-type="bibr">20</xref>]. An AHA scientific statement from 2019 suggests that secondary preventive therapies might be considered on an individual basis in patients with MINOCA [<xref rid="pone.0324072.ref020" ref-type="bibr">20</xref>]. The guidelines from European Society of cardiology from 2020 recommend that patients with MINOCA, of unknown cause, might be followed-up similarly to patients diagnosed with MI with obstructive coronary arteries (MI-CAD), and be treated according to secondary prevention guidelines for atherosclerotic disease (class IIb recommendation) [<xref rid="pone.0324072.ref002" ref-type="bibr">2</xref>]. Recommendation on duration of the treatment is however scarce. The percentage prescribed secondary preventive drugs has been shown to be lower in patients with MINOCA than in those with MI-CAD in clinical routine [<xref rid="pone.0324072.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0324072.ref022" ref-type="bibr">22</xref>]. However, knowledge is lacking regarding adherence to medical treatment in patients with MINOCA and whether the different medication adherence measures, including initiation, implementation, and persistence rates of secondary preventive drug treatment differ between patients with MINOCA and MI-CAD. We therefore aim to evaluate the adherence to guideline recommended medications in patients with MINOCA and MI-CAD.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Patient selection</title><p>The present study is a Swedish nationwide register-based cohort study, based on the 155,518 unique patients in the SWEDEHEART registry [<xref rid="pone.0324072.ref023" ref-type="bibr">23</xref>], who were hospitalised due to acute MI and discharged between January 1, 2006 and December 31, 2017. Patient with at least one coronary stenosis &#x02265;50% at coronary angiography were labelled MI-CAD and patients without were labelled MINOCA. Patients were excluded if they did not undergo in-hospital diagnostic coronary angiography, if their result of the coronary angiography was unknown, died within 30 days after discharge, or were receiving automatically dispensed doses of medication before admission to hospital. Patients who previously underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) were included in the MI-CAD group independently on findings at the latest coronary angiography. The final study cohort consisted of 116,378 individuals, 9138 with MINOCA and 107,240 with MI-CAD (<xref rid="pone.0324072.g001" ref-type="fig">Fig 1</xref>). Patient were followed from the date of hospital discharge to the date of death or end of the study period, whichever occurred first. Patients were censored at death or and at the end of the study period.</p><fig position="float" id="pone.0324072.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.g001</object-id><label>Fig 1</label><caption><title>Study population.</title><p>Patients were excluded if they did not undergo in-hospital diagnostic coronary angiography, if their result of the coronary angiography is unknown, died within 30 days after discharge, or were automatically dispensed doses of medication. Patients with previous PCI or CABG were considered to have a MI-CAD.</p></caption><graphic xlink:href="pone.0324072.g001" position="float"/></fig></sec><sec id="sec008"><title>Data sources</title><p>This study used data from three Swedish national registries linked through the unique social security number that all Swedish citizens have. The data from SWEDEHEART were merged with census data (migration and death) for the Swedish population and two Swedish population-based mandatory national registries maintained by the National Board of Health and Welfare: the &#x02018;Patient Register,&#x02019; which includes all ICD-codes for all hospital admissions [<xref rid="pone.0324072.ref024" ref-type="bibr">24</xref>], and the &#x02018;Prescribed Drug Register,&#x02019; which contains data from pharmacies on drugs prescribed to individual patients [<xref rid="pone.0324072.ref025" ref-type="bibr">25</xref>].</p><p>Data on medication at hospital admission and hospital discharge were retrieved from the SWEDEHEART registry. Data regarding filled prescriptions for medications 6 months before hospital admission, and 1 and 6 months and 1&#x02013;3 and 5 years after hospital admission, were retrieved from the Prescribed Drug Register.</p><p>Data on prescriptions for the following pharmaceuticals were included: acetylsalicylic acid (ATC-code B01AC06); P2Y12-inhibitors (B01AC04, B01AC22 and B01AC24); statins (C10AA and C10BA); beta blockers (C07); ACEs/ARBs including fixed combinations with thiazides (C09); Vitamin K antagonists (B01AA03); and novel oral anticoagulants (B01AE07, B01AF01, B01AF02 and B01AF03).</p><p>The study was approved by the Regional Ethical Review Board in Stockholm (diary number: 2012/60&#x02013;31/2) and by the Swedish Ethical Review Authority (diary number: 2020&#x02013;04252).</p></sec><sec id="sec009"><title>Assessment of prescribing and medication adherence</title><p>All three constructs of adherence to medication, namely initiation, implementation and persistence, were evaluated [<xref rid="pone.0324072.ref026" ref-type="bibr">26</xref>]. In assessing adherence to medication only patients who received their first prescription for the above-mentioned drugs at hospital discharge were included, to minimize selection bias, as the prevalence of medications at admission differed significantly in the MINOCA and MI-CAD cohorts. Patients with ongoing use of a certain drug class and those prescribed a certain drug class within 6 months prior to MI were excluded from analyses on that particular drug class; however, these patients were eligible for inclusion and analysis regarding prescription of other drug classes.</p><p>The time of follow-up was divided into six periods, 2&#x02013;6 months, 6&#x02013;12 months, 1&#x02013;2 years, 2&#x02013;3 years and 3&#x02013;5 years (<xref rid="pone.0324072.g002" ref-type="fig">Fig 2</xref>).</p><fig position="float" id="pone.0324072.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.g002</object-id><label>Fig 2</label><caption><title> Study design. Time line demonstrating the times for initiation, implementation, and persistence of secondary preventive medications. Initiation; a filled prescription within 30 days after discharge. Persistence; the length of time between initiation and discontinuation of medical treatment (&#x0003e;45 days without refilled prescription). Non-persistent; patients discontinued treatment. Restarter; patients restarting treatment after being considered non-persistent. Users; the sum of persistent and restarting patients. Implementation: the extent to which a patient&#x02019;s actual dosing regimen corresponded to the prescribed dosing regimen.</title></caption><graphic xlink:href="pone.0324072.g002" position="float"/></fig></sec><sec id="sec010"><title>Initiation</title><p>Initiation was defined as the percentage of patients who had a drug prescription from a physician and dispensed the drug at a pharmacy within 30 days after discharge. Only patients who initiated medication were included in further analyses of implementation, discontinuation and persistence of that drug class.</p></sec><sec id="sec011"><title>Implementation</title><p>Drug implementation, defined as the extent to which a patient&#x02019;s actual dosing regimen corresponded to the prescribed dosing regimen, was estimated by determining the medication possession ratio (MPR) [<xref rid="pone.0324072.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0324072.ref027" ref-type="bibr">27</xref>]. Briefly, for each time-period, the number of days a drug was available was divided by the number of days in that time-period. Stockpiling was included. The proportion of days with drug available was categorized as &#x0003c;50%, 50&#x02013;80% and 80&#x02013;100%, with an MPR&#x02009;&#x02265;&#x02009;80% defined as high implementation [<xref rid="pone.0324072.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0324072.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0324072.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0324072.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0324072.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0324072.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0324072.ref029" ref-type="bibr">29</xref>].</p></sec><sec id="sec012"><title>Persistence</title><p>Persistence in the present study was defined as the length of time between initiation and discontinuation of medical treatment. Patients were regarded as taking a drug as long as the prescription was refilled within the estimated time of the previous prescription, including drugs carried over from previous prescriptions. A grace period of 45 days was allowed, in which patients were considered continuously exposed to a drug if they refilled a prescription within 45 days after the estimated completion of previous prescriptions (<xref rid="pone.0324072.g002" ref-type="fig">Fig 2</xref>). The 45-day grace period were used to establish a reasonable balance between the need for monitoring short-term implementation and long-term persistence [<xref rid="pone.0324072.ref027" ref-type="bibr">27</xref>].</p><p>Patients were allowed to switch between drugs within the same drug class and still be considered persistent. If a patient failed to fill a new prescription within a given time, the date of non-persistence was defined as the calculated end of supply from the most recent prescription, including any stockpiling. On the first day of each interval, the proportion of persistent patients was calculated by dividing the number of persistent patients by the number of patients remaining in the cohort.</p><p>Patients who discontinued treatment were labeled non-persistent. Those who restarted treatment after being considered non-persistent were followed as a separate restarter group. The group users was defined as the sum of persistent and restarting patients. This provided an opportunity to capture patients restarting treatment after non-persistence and to calculate the actual proportion of patients receiving treatment at a certain time. The proportion of persistent patients at different time points was calculated by dividing the number of persistent patients by the number of patients remaining in the cohort at the first day of each interval,</p><p>Implementation was assessed only in patients who were persistent or users, to avoid confusing low implementation with non-persistence.</p><p>Patients who discontinued treatment and didn&#x000b4;t refill their prescription within 45 days were labeled non-persistent, whereas patients who continued to refill their prescription but took their medication less than 80% of the days were labeled persistent with low implementation.</p></sec><sec id="sec013"><title>Statistics</title><p>Normally distributed continuous variables were presented as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) and compared by Students&#x02019; t-tests, whereas non normally distributed continuous variables were presented as median and inter quartile range (IQR) and compared by Mann Whitney U-tests. Categorical variables were presented as frequencies and compared by Chi-square test. Multivariable logistic regression analyses were performed to investigate the association between MINOCA/MI-CAD status and the persistence of included medications at 12 months, adjusted for previously established cardiovascular risk factors like age, BMI, smoking, previous MI, hypertension, heart failure, diabetes, kidney failure, PVD, stroke, and COPD. The model for statins was also adjusted for non-HLD cholesterol. Logistic and linear regressions including implementation and persistence data, as well as different cardiovascular risk factors, were used as exploratory sensitivity analyses.</p><p>Statistical analyses were performed using SAS Software Version 9.4 (SAS Institute, Cary, NC, USA) and the Predictive Analytical SoftWare (PASW statistics 17.03) program (SPSS Inc, Chicago, IL, USA). All statistical tests were two-tailed, with p&#x02009;&#x0003c;&#x02009;0.05 regarded as statistically significant.</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><p>A total of 9,138 patients diagnosed with MINOCA and 107,240 diagnosed with MI-CAD were followed-up for a mean 5.9 years. MINOCA patients were more often younger women with few risk factors for cardiovascular disease (<xref rid="pone.0324072.t001" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="pone.0324072.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.t001</object-id><label>Table 1</label><caption><title>Baseline demographic and clinical characteristics of the study population.</title></caption><alternatives><graphic xlink:href="pone.0324072.t001" id="pone.0324072.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">MINOCA</th><th align="left" rowspan="1" colspan="1">MI-CAD</th><th align="left" rowspan="1" colspan="1">p-value*</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Total, n</bold>
</td><td align="left" rowspan="1" colspan="1">9138</td><td align="left" rowspan="1" colspan="1">107240</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Demographics</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female, n (%)</td><td align="left" rowspan="1" colspan="1">5774 (63.2)</td><td align="left" rowspan="1" colspan="1">30191 (28.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, y, mean (&#x000b1;SD)</td><td align="left" rowspan="1" colspan="1">66 (11.6)</td><td align="left" rowspan="1" colspan="1">67 (11.4)</td><td align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Risk factors, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Never</td><td align="left" rowspan="1" colspan="1">4099 (44.9)</td><td align="left" rowspan="1" colspan="1">40742 (38.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Previous</td><td align="left" rowspan="1" colspan="1">2986 (32.7)</td><td align="left" rowspan="1" colspan="1">35004 (32.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Current</td><td align="left" rowspan="1" colspan="1">1672 (18.3)</td><td align="left" rowspan="1" colspan="1">27464 (25.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="left" rowspan="1" colspan="1">374 (4.1)</td><td align="left" rowspan="1" colspan="1">3936 (3.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">1144 (12.5)</td><td align="left" rowspan="1" colspan="1">20008 (18.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">1815 (19.9)</td><td align="left" rowspan="1" colspan="1">21397 (20.0)</td><td align="left" rowspan="1" colspan="1">0.836</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI kg/m<sup>2</sup>, mean (&#x000b1;SD)</td><td align="left" rowspan="1" colspan="1">26.9 (9.3)</td><td align="left" rowspan="1" colspan="1">27.2 (5.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Medical history, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">COPD</td><td align="left" rowspan="1" colspan="1">805 (8.8)</td><td align="left" rowspan="1" colspan="1">5162 (4.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Kidney failure</td><td align="left" rowspan="1" colspan="1">101 (1.1)</td><td align="left" rowspan="1" colspan="1">1690 (1.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart failure</td><td align="left" rowspan="1" colspan="1">301 (3.3)</td><td align="left" rowspan="1" colspan="1">2805 (2.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous MI</td><td align="left" rowspan="1" colspan="1">137 (1.5)</td><td align="left" rowspan="1" colspan="1">4030 (3.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2845 (2.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PCI</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2654 (2.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PVD</td><td align="left" rowspan="1" colspan="1">169 (1.8)</td><td align="left" rowspan="1" colspan="1">3208 (3.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">405 (4.4)</td><td align="left" rowspan="1" colspan="1">5678 (5.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Laboratory findings</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-HDL mmol/L, mean (&#x000b1;SD)</td><td align="left" rowspan="1" colspan="1">3.6 (1.1)</td><td align="left" rowspan="1" colspan="1">3.9 (1.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ECG at presention, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ST-elevation</td><td align="left" rowspan="1" colspan="1">1234 (13.6)</td><td align="left" rowspan="1" colspan="1">44502 (41.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">728 (8.0)</td><td align="left" rowspan="1" colspan="1">6131 (5.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>LVEF during hospital stay, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;50%</td><td align="left" rowspan="1" colspan="1">5639 (74.3)</td><td align="left" rowspan="1" colspan="1">55556 (60.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">40-49%</td><td align="left" rowspan="1" colspan="1">1074 (14.1)</td><td align="left" rowspan="1" colspan="1">20306 (22.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">30-39%</td><td align="left" rowspan="1" colspan="1">566 (7.5)</td><td align="left" rowspan="1" colspan="1">11222 (12.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;30%</td><td align="left" rowspan="1" colspan="1">247 (3.3)</td><td align="left" rowspan="1" colspan="1">3754 (4.1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1">66 (0.9)</td><td align="left" rowspan="1" colspan="1">823 (0.9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Medication prior admission, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">1666 (18.2)</td><td align="left" rowspan="1" colspan="1">22662 (21.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE-inhibitor or ARB</td><td align="left" rowspan="1" colspan="1">2679 (29.3)</td><td align="left" rowspan="1" colspan="1">29463 (27.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta blocker</td><td align="left" rowspan="1" colspan="1">2184 (23.9)</td><td align="left" rowspan="1" colspan="1">25500 (23.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DAPT</td><td align="left" rowspan="1" colspan="1">116 (6.6)</td><td align="left" rowspan="1" colspan="1">1795 (7.6)</td><td align="left" rowspan="1" colspan="1">0.134</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-vitamin K anticoagulant</td><td align="left" rowspan="1" colspan="1">68 (0.7)</td><td align="left" rowspan="1" colspan="1">591 (0.6)</td><td align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" rowspan="1" colspan="1">P2Y12-inhibitor</td><td align="left" rowspan="1" colspan="1">207 (2.3)</td><td align="left" rowspan="1" colspan="1">2805 (2.6)</td><td align="left" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">1649 (18.1)</td><td align="left" rowspan="1" colspan="1">20752 (19.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Warfarin</td><td align="left" rowspan="1" colspan="1">380 (4.2)</td><td align="left" rowspan="1" colspan="1">2958 (2.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Medication at discharge, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">8053 (88.1)</td><td align="left" rowspan="1" colspan="1">103177 (96.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEI/ARB</td><td align="left" rowspan="1" colspan="1">5914 (64.7)</td><td align="left" rowspan="1" colspan="1">86166 (80.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta blocker</td><td align="left" rowspan="1" colspan="1">7335 (80.3)</td><td align="left" rowspan="1" colspan="1">97288 (90.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DAPT</td><td align="left" rowspan="1" colspan="1">5950 (65.1)</td><td align="left" rowspan="1" colspan="1">92553 (86.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-vitamin K anticoagulant</td><td align="left" rowspan="1" colspan="1">230 (2.5)</td><td align="left" rowspan="1" colspan="1">1818 (1.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">P2Y12-inhibitor</td><td align="left" rowspan="1" colspan="1">6264 (68.5)</td><td align="left" rowspan="1" colspan="1">95506 (89.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">7741 (84.7)</td><td align="left" rowspan="1" colspan="1">102383 (95.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Warfarin</td><td align="left" rowspan="1" colspan="1">708 (7.8)</td><td align="left" rowspan="1" colspan="1">5534 (5.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>New prescriptions at discharge, n (%)**</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">6474/7418 (87.3)</td><td align="left" rowspan="1" colspan="1">80303/83604 (96.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEI/ARB</td><td align="left" rowspan="1" colspan="1">3320/6401 (51.9)</td><td align="left" rowspan="1" colspan="1">57099/76513 (74.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta blocker</td><td align="left" rowspan="1" colspan="1">5209/6894 (75.6)</td><td align="left" rowspan="1" colspan="1">71593/80461 (89.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">6102/7444 (82.0)</td><td align="left" rowspan="1" colspan="1">81218/85538 (94.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">P2Y12-inhibitor</td><td align="left" rowspan="1" colspan="1">6053/8857 (68.3)</td><td align="left" rowspan="1" colspan="1">91792/103034 (89.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>* P-value: difference between MI-CAD and MINOCA.</p></fn><fn id="t001fn002"><p>** Prescriptions in patients without ongoing treatment or prescriptions 6 months prior myocardial infarction.</p></fn><fn id="t001fn003"><p>ACEI/ARB, ACE-inhibitor or angiotensin-receptor blocker; BMI, body mass index; CABG, coronary bypass grafting; COPD, chronic obstructive pulmonary disease; DAPT, dual antiplatelet therapy; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.</p></fn></table-wrap-foot></table-wrap><sec id="sec015"><title>Prescription and initiation</title><p>Patients with MINOCA were as expected less often prescribed and initiated on treatment with all assessed drug classes than patients with MI-CAD (<xref rid="pone.0324072.s001" ref-type="supplementary-material">S1 Table</xref>).</p></sec><sec id="sec016"><title>Implementation</title><p>Implementation, defined as the extent to which a patient&#x02019;s actual dosing regimen corresponded to the prescribed dosing regimen, was highest at the beginning of follow-up and declined slowly over time. However, the proportions of patients with high implementation to treatment with aspirin, ACEI/ARBs, and beta blockers during all time periods were high in both the MINOCA and MI-CAD groups. The proportion of patients with high implementation to treatment with statins was lower in both the MINOCA and MI-CAD groups (<xref rid="pone.0324072.g003" ref-type="fig">Figs 3</xref> and <xref rid="pone.0324072.g004" ref-type="fig">4</xref>, <xref rid="pone.0324072.s002" ref-type="supplementary-material">S2 Table</xref>).</p><fig position="float" id="pone.0324072.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.g003</object-id><label>Fig 3</label><caption><title>Implementation of aspirin and statins as secondary preventive treatment.</title><p>Implementation, e.g., the extent to which a patient&#x02019;s actual dosing regimen corresponded to the prescribed dosing regimen, in patients with MINOCA and MI-CAD. A medication possession ratio (MPR) &#x02265; 80% was defined as high implementation.</p></caption><graphic xlink:href="pone.0324072.g003" position="float"/></fig><fig position="float" id="pone.0324072.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.g004</object-id><label>Fig 4</label><caption><title>Implementation of ACEI/ARB and beta blockers as secondary preventive treatment.</title><p>Implementation, e.g., the extent to which a patient&#x02019;s actual dosing regimen corresponded to the prescribed dosing regimen, in patients with MINOCA and MI-CAD. A medication possession ratio (MPR) &#x02265; 80% was defined as high implementation.</p></caption><graphic xlink:href="pone.0324072.g004" position="float"/></fig></sec><sec id="sec017"><title>Persistence</title><p>Patients with MINOCA had lower persistence to all studied drug classes than patients with MI-CAD (<xref rid="pone.0324072.g005" ref-type="fig">Figs 5</xref> and <xref rid="pone.0324072.g006" ref-type="fig">6</xref>, <xref rid="pone.0324072.s001" ref-type="supplementary-material">S1 Table</xref>). The addition of restarting to persistent patients increased the rates of users of all classes of drugs, thus the difference between MINOCA and MI-CAD remained. Multivariable logistic regression analyses, after adjustment for relevant covariates, showed that persistence at 12 months remained significantly lower in the MINOCA than in the MI-CAD group (<xref rid="pone.0324072.t002" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="pone.0324072.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.t002</object-id><label>Table 2</label><caption><title>Logistic regression models of factors associated with persistence of the investigated medications at 12 months.</title></caption><alternatives><graphic xlink:href="pone.0324072.t002" id="pone.0324072.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">Univariate regression</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">Multivariable regression</th><th align="left" rowspan="1" colspan="1">P-value</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">MI-CAD</td><td align="left" rowspan="1" colspan="1">68576</td><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MINOCA</td><td align="left" rowspan="1" colspan="1">5556</td><td align="left" rowspan="1" colspan="1">0.365 (0.338-0.395)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.324 (0.299-0.358)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins</td><td align="left" rowspan="1" colspan="1">MI-CAD</td><td align="left" rowspan="1" colspan="1">69730</td><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MINOCA</td><td align="left" rowspan="1" colspan="1">5227</td><td align="left" rowspan="1" colspan="1">0.285 (0.263-0.309)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.327 (0.294-0.363)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ACEI/ARBs</td><td align="left" rowspan="1" colspan="1">MI-CAD</td><td align="left" rowspan="1" colspan="1">2810</td><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MINOCA</td><td align="left" rowspan="1" colspan="1">49015</td><td align="left" rowspan="1" colspan="1">0.478 (0.429-0.532)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.519 (0.461-0.584)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Betablockers</td><td align="left" rowspan="1" colspan="1">MI-CAD</td><td align="left" rowspan="1" colspan="1">61734</td><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ref.</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MINOCA</td><td align="left" rowspan="1" colspan="1">4521</td><td align="left" rowspan="1" colspan="1">0.477 (0.441-0.515)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.467 (0.428-0.509)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>All multivariate analyses were adjusted for MINOCA/MI-CAD status, gender, age, BMI, smoking, previous MI, hypertension, heart failure, diabetes, kidney failure, PVD, stroke, and COPD. The model for statins was also adjusted for non-HLD cholesterol.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="pone.0324072.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.g005</object-id><label>Fig 5</label><caption><title>Persistence of treatment with aspirin and statins.</title><p>Persistence; the length of time between initiation and discontinuation of medical treatment. Restarter; patients restarting treatment after being considered non-persistent. Users; the sum of persistent and restarting patients. On the first day of each interval, the proportion of persistent patients was calculated by dividing the number of persistent patients by the number of patients remaining in the cohort.</p></caption><graphic xlink:href="pone.0324072.g005" position="float"/></fig><fig position="float" id="pone.0324072.g006"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.g006</object-id><label>Fig 6</label><caption><title>Persistence of treatment with ACEI/ARB and beta blockers.</title><p>Persistence; the length of time between initiation and discontinuation of medical treatment. Restarter; patients restarting treatment after being considered non-persistent. Users; the sum of persistent and restarting patients. On the first day of each interval, the proportion of persistent patients was calculated by dividing the number of persistent patients by the number of patients remaining in the cohort.</p></caption><graphic xlink:href="pone.0324072.g006" position="float"/></fig></sec><sec id="sec018"><title>Implementation and persistence in women</title><p>A subgroup analysis of women showed that rates of implementation of aspirin and statins were significantly higher in patients with MI-CAD than in those with MINOCA, whereas there were no difference in implementation rates of ACE/ARBs and beta blockers (<xref rid="pone.0324072.t003" ref-type="table">Table 3</xref>). Persistence remained significantly higher in women with MI-CAD than in those with MINOCA (<xref rid="pone.0324072.t004" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="pone.0324072.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.t003</object-id><label>Table 3</label><caption><title>Implementation of secondary preventive treatment in women with MINOCA and MI-CAD. A MPR&#x02009;&#x02265;&#x02009;80% was defined as good adherence.</title></caption><alternatives><graphic xlink:href="pone.0324072.t003" id="pone.0324072.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Aspirin</th><th align="left" rowspan="1" colspan="1">MINOCA</th><th align="left" rowspan="1" colspan="1">MI-CAD</th><th align="left" rowspan="1" colspan="1">p-value</th><th align="left" rowspan="1" colspan="1">Statin</th><th align="left" rowspan="1" colspan="1">MINOCA</th><th align="left" rowspan="1" colspan="1">MI-CAD</th><th align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;6 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">3268</td><td align="left" rowspan="1" colspan="1">18774</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;6 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">3099</td><td align="left" rowspan="1" colspan="1">18156</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">3197 (97.8%)</td><td align="left" rowspan="1" colspan="1">18467 (98.4%)</td><td align="left" rowspan="1" colspan="1">0.044</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">2803 (90.4%)</td><td align="left" rowspan="1" colspan="1">18156 (94.0%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">55 (1.7%)</td><td align="left" rowspan="1" colspan="1">255 (1.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">259 (8.4%)</td><td align="left" rowspan="1" colspan="1">1053 (5.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">16 (0.5%)</td><td align="left" rowspan="1" colspan="1">52 (0.3%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">37 (1.2%)</td><td align="left" rowspan="1" colspan="1">113 (0.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 6&#x02013;12 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">2874</td><td align="left" rowspan="1" colspan="1">17025</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 6&#x02013;12 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">2613</td><td align="left" rowspan="1" colspan="1">17277</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">2749 (95.7%)</td><td align="left" rowspan="1" colspan="1">16586 (97.4%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">2353 (90.0%)</td><td align="left" rowspan="1" colspan="1">16170 (93.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">98 (3.4%)</td><td align="left" rowspan="1" colspan="1">353 (2.1%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">205 (7.8%)</td><td align="left" rowspan="1" colspan="1">935 (5.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">27 (0.9%)</td><td align="left" rowspan="1" colspan="1">86 (0.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">55 (2.1%)</td><td align="left" rowspan="1" colspan="1">172 (1.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 1&#x02013;2 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">2422</td><td align="left" rowspan="1" colspan="1">14579</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 1&#x02013;2 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">14156</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">2297 (94.8%)</td><td align="left" rowspan="1" colspan="1">14154 (97.1%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1746 (86.4%)</td><td align="left" rowspan="1" colspan="1">13016 (91.9%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">98 (4.0%)</td><td align="left" rowspan="1" colspan="1">368 (2.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">228 (11.3%)</td><td align="left" rowspan="1" colspan="1">963 (6.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">27 (1.1%)</td><td align="left" rowspan="1" colspan="1">57 (0.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">48 (2.4%)</td><td align="left" rowspan="1" colspan="1">177 (1.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;3 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">2069</td><td align="left" rowspan="1" colspan="1">12348</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;3 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">1645</td><td align="left" rowspan="1" colspan="1">11668</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1946 (94.1%)</td><td align="left" rowspan="1" colspan="1">11959 (96.8%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1390 (84.5%)</td><td align="left" rowspan="1" colspan="1">10569 (90.6%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">106 (5.1%)</td><td align="left" rowspan="1" colspan="1">329 (2.7%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">205 (12.5%)</td><td align="left" rowspan="1" colspan="1">903 (7.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">17 (0.8%)</td><td align="left" rowspan="1" colspan="1">60 (0.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">50 (3.0%)</td><td align="left" rowspan="1" colspan="1">196 (1.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 3&#x02013;5 years</bold>
</td><td align="left" rowspan="1" colspan="1">1468</td><td align="left" rowspan="1" colspan="1">8533</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 3&#x02013;5 years</bold>
</td><td align="left" rowspan="1" colspan="1">1077</td><td align="left" rowspan="1" colspan="1">7692</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1377 (93.8%)</td><td align="left" rowspan="1" colspan="1">8268 (96.9%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">862 (80.0%)</td><td align="left" rowspan="1" colspan="1">6684 (86.9%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">75 (5.1%)</td><td align="left" rowspan="1" colspan="1">266 (2.6%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">167 (15.5%)</td><td align="left" rowspan="1" colspan="1">838 (10.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">16 (1.1%)</td><td align="left" rowspan="1" colspan="1">39 (0.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">48 (4.5%)</td><td align="left" rowspan="1" colspan="1">170 (2.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ACEI/ARI</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>MINOCA</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>MI-CAD</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>p-value</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Betablockade</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>MINOCA</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>MI-CAD</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>p-value</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;6 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">1684</td><td align="left" rowspan="1" colspan="1">12982</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;6 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">2481</td><td align="left" rowspan="1" colspan="1">15824</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1650 (98.0%)</td><td align="left" rowspan="1" colspan="1">12803 (98.6%)</td><td align="left" rowspan="1" colspan="1">0.011</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">2353 (95.2%)</td><td align="left" rowspan="1" colspan="1">15253 (96.4%)</td><td align="left" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">29 (1.7%)</td><td align="left" rowspan="1" colspan="1">124 (1.0%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">83 (3.3%)</td><td align="left" rowspan="1" colspan="1">396 (2.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">5 (0.3%)</td><td align="left" rowspan="1" colspan="1">55 (0.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">35 (1.4%)</td><td align="left" rowspan="1" colspan="1">172 (1.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 6&#x02013;12 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">1480</td><td align="left" rowspan="1" colspan="1">11661</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 6&#x02013;12 months (n)</bold>
</td><td align="left" rowspan="1" colspan="1">2190</td><td align="left" rowspan="1" colspan="1">14213</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1442 (97.4%)</td><td align="left" rowspan="1" colspan="1">11453 (98.2%)</td><td align="left" rowspan="1" colspan="1">0.080</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">2066 (94.3%</td><td align="left" rowspan="1" colspan="1">13525 (95.2%)</td><td align="left" rowspan="1" colspan="1">0.240</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">27 (1.8%)</td><td align="left" rowspan="1" colspan="1">159 (1.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">87 (4.0%)</td><td align="left" rowspan="1" colspan="1">493 (3.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">11 (0.7%)</td><td align="left" rowspan="1" colspan="1">49 (0.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">37 (1.7%)</td><td align="left" rowspan="1" colspan="1">195 (1.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 1&#x02013;2 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">1226</td><td align="left" rowspan="1" colspan="1">9912</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 1&#x02013;2 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">1848</td><td align="left" rowspan="1" colspan="1">12082</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1197 (97.6%)</td><td align="left" rowspan="1" colspan="1">9720 (98.1%)</td><td align="left" rowspan="1" colspan="1">0.479</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1727 (93.5%)</td><td align="left" rowspan="1" colspan="1">11388 (94.3%)</td><td align="left" rowspan="1" colspan="1">0.371</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">23 (1.9%)</td><td align="left" rowspan="1" colspan="1">142 (1.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">91 (4.9%)</td><td align="left" rowspan="1" colspan="1">531 (4.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">6 (0.5%)</td><td align="left" rowspan="1" colspan="1">50 (0.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">30 (1.6%)</td><td align="left" rowspan="1" colspan="1">163 (1.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;3 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">1052</td><td align="left" rowspan="1" colspan="1">8358</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 2&#x02013;3 years (n)</bold>
</td><td align="left" rowspan="1" colspan="1">1557</td><td align="left" rowspan="1" colspan="1">10260</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1029 (97.8%)</td><td align="left" rowspan="1" colspan="1">8181 (97.9%)</td><td align="left" rowspan="1" colspan="1">0.361</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1473 (94.6%)</td><td align="left" rowspan="1" colspan="1">9752 (95.0%)</td><td align="left" rowspan="1" colspan="1">0.564</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">19 (1.8%)</td><td align="left" rowspan="1" colspan="1">121 (1.4%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">66 (4.2%)</td><td align="left" rowspan="1" colspan="1">380 (3.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">4 (0.4%)</td><td align="left" rowspan="1" colspan="1">56 (0.7%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">18 (1.2%)</td><td align="left" rowspan="1" colspan="1">128 (1.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MPR 3&#x02013;5 years</bold>
</td><td align="left" rowspan="1" colspan="1">744</td><td align="left" rowspan="1" colspan="1">5674</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MPR 3&#x02013;5 years</bold>
</td><td align="left" rowspan="1" colspan="1">1132</td><td align="left" rowspan="1" colspan="1">7151</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">723 (97.2%)</td><td align="left" rowspan="1" colspan="1">5559 (98.0%)</td><td align="left" rowspan="1" colspan="1">0.290</td><td align="left" rowspan="1" colspan="1">80-100%</td><td align="left" rowspan="1" colspan="1">1065 (94.1%)</td><td align="left" rowspan="1" colspan="1">6791 (95.0%)</td><td align="left" rowspan="1" colspan="1">0.326</td></tr><tr><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">17 (2.3%)</td><td align="left" rowspan="1" colspan="1">86 (1.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50-80%</td><td align="left" rowspan="1" colspan="1">49 (4.3%)</td><td align="left" rowspan="1" colspan="1">279 (3.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">4 (0.5%)</td><td align="left" rowspan="1" colspan="1">29 (0.5%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;50%</td><td align="left" rowspan="1" colspan="1">18 (1.6%)</td><td align="left" rowspan="1" colspan="1">81 (1.1%)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>*p-value compares persistent patients with MINOCA and persistent patient with MI-CAD. ACEI/ARB: ACE Inhibitor or angiotensin receptor blocker.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pone.0324072.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0324072.t004</object-id><label>Table 4</label><caption><title>Adherence to medication in women. Only patients with a de novo prescription of a drug class are included in analysis of that particular drug class. Patients with ongoing treatment or a prescription six months prior to myocardial infarction were excluded from analysis of that particular drug class.</title></caption><alternatives><graphic xlink:href="pone.0324072.t004" id="pone.0324072.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">MINOCA</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">MI-CAD</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Persistent</th><th align="left" rowspan="1" colspan="1">Restarters</th><th align="left" rowspan="1" colspan="1">Users</th><th align="left" rowspan="1" colspan="1">Cohort</th><th align="left" rowspan="1" colspan="1">Persistent</th><th align="left" rowspan="1" colspan="1">Restarters</th><th align="left" rowspan="1" colspan="1">Users</th><th align="left" rowspan="1" colspan="1">Cohort</th><th align="left" rowspan="1" colspan="1">p-value*</th><th align="left" rowspan="1" colspan="1">p-value**</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Statin</bold>
</td><td align="left" rowspan="1" colspan="1">4675</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">23887</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prescribed, n (%)</td><td align="left" rowspan="1" colspan="1">3768 (80.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22167 (92.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary adherence</td><td align="left" rowspan="1" colspan="1">3587 (95.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21299 (96.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 months, n (%)</td><td align="left" rowspan="1" colspan="1">3523 (99.8)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3523 (99.8)</td><td align="left" rowspan="1" colspan="1">3529</td><td align="left" rowspan="1" colspan="1">20773 (99.7)</td><td align="left" rowspan="1" colspan="1">14 (0.1)</td><td align="left" rowspan="1" colspan="1">20787 (99.8)</td><td align="left" rowspan="1" colspan="1">20833</td><td align="left" rowspan="1" colspan="1">0.055</td><td align="left" rowspan="1" colspan="1">0.546</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 6 months, n (%)</td><td align="left" rowspan="1" colspan="1">3052 (89.2)</td><td align="left" rowspan="1" colspan="1">51 (1.5)</td><td align="left" rowspan="1" colspan="1">3103 (90.7)</td><td align="left" rowspan="1" colspan="1">3422</td><td align="left" rowspan="1" colspan="1">19166 (95.6)</td><td align="left" rowspan="1" colspan="1">197 (1.0)</td><td align="left" rowspan="1" colspan="1">19363 (96.5)</td><td align="left" rowspan="1" colspan="1">20049</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 1 year, n (%)</td><td align="left" rowspan="1" colspan="1">2455 (75.3)</td><td align="left" rowspan="1" colspan="1">224 (6.9)</td><td align="left" rowspan="1" colspan="1">2679 (82.2)</td><td align="left" rowspan="1" colspan="1">3259</td><td align="left" rowspan="1" colspan="1">16655 (88.4)</td><td align="left" rowspan="1" colspan="1">814 (4.3)</td><td align="left" rowspan="1" colspan="1">17469 (92.7)</td><td align="left" rowspan="1" colspan="1">18845</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 year, n (%)</td><td align="left" rowspan="1" colspan="1">1727 (59.3)</td><td align="left" rowspan="1" colspan="1">374 (12.8)</td><td align="left" rowspan="1" colspan="1">2101 (72.1)</td><td align="left" rowspan="1" colspan="1">2913</td><td align="left" rowspan="1" colspan="1">12966 (77.6)</td><td align="left" rowspan="1" colspan="1">1472 ((8.8)</td><td align="left" rowspan="1" colspan="1">14438 (86.5)</td><td align="left" rowspan="1" colspan="1">16701</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 3 year, n (%)</td><td align="left" rowspan="1" colspan="1">1325 (51.5)</td><td align="left" rowspan="1" colspan="1">385 (15.0)</td><td align="left" rowspan="1" colspan="1">1710 (66.4)</td><td align="left" rowspan="1" colspan="1">2574</td><td align="left" rowspan="1" colspan="1">10320 (71.1)</td><td align="left" rowspan="1" colspan="1">1661 (11.4)</td><td align="left" rowspan="1" colspan="1">11981 (82.5)</td><td align="left" rowspan="1" colspan="1">14522</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 5 years, n (%)</td><td align="left" rowspan="1" colspan="1">793 (41.4)</td><td align="left" rowspan="1" colspan="1">376 (19.6)</td><td align="left" rowspan="1" colspan="1">1169 (61.0)</td><td align="left" rowspan="1" colspan="1">1917</td><td align="left" rowspan="1" colspan="1">6249 (60.1)</td><td align="left" rowspan="1" colspan="1">1763 (17.0)</td><td align="left" rowspan="1" colspan="1">8012 (77.0)</td><td align="left" rowspan="1" colspan="1">10401</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ASA</bold>
</td><td align="left" rowspan="1" colspan="1">4645</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22862</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prescribed, n (%)</td><td align="left" rowspan="1" colspan="1">4013 (86.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21757 (95.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary adherence</td><td align="left" rowspan="1" colspan="1">3817 (95.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20865 (95.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.033</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 months, n (%)</td><td align="left" rowspan="1" colspan="1">3750 (100)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3750 (100)</td><td align="left" rowspan="1" colspan="1">3751</td><td align="left" rowspan="1" colspan="1">20376 (100)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">20376 (100)</td><td align="left" rowspan="1" colspan="1">20388</td><td align="left" rowspan="1" colspan="1">0.094</td><td align="left" rowspan="1" colspan="1">0.491</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 6 months, n (%)</td><td align="left" rowspan="1" colspan="1">3233 (89.2)</td><td align="left" rowspan="1" colspan="1">35 (1.0)</td><td align="left" rowspan="1" colspan="1">3268 (90.1)</td><td align="left" rowspan="1" colspan="1">3626</td><td align="left" rowspan="1" colspan="1">18617 (94.9)</td><td align="left" rowspan="1" colspan="1">155 (0.8)</td><td align="left" rowspan="1" colspan="1">18772 (95.7)</td><td align="left" rowspan="1" colspan="1">19616</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 1 year, n (%)</td><td align="left" rowspan="1" colspan="1">2780 (80.8)</td><td align="left" rowspan="1" colspan="1">138 (4.0)</td><td align="left" rowspan="1" colspan="1">2918 (84.8)</td><td align="left" rowspan="1" colspan="1">3441</td><td align="left" rowspan="1" colspan="1">16610 (90.2)</td><td align="left" rowspan="1" colspan="1">580 (3.2)</td><td align="left" rowspan="1" colspan="1">17190 (93.4)</td><td align="left" rowspan="1" colspan="1">18412</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 year, n (%)</td><td align="left" rowspan="1" colspan="1">2211 (71.8)</td><td align="left" rowspan="1" colspan="1">265 (8.6)</td><td align="left" rowspan="1" colspan="1">2476 (80.4)</td><td align="left" rowspan="1" colspan="1">3080</td><td align="left" rowspan="1" colspan="1">13688 (84.1)</td><td align="left" rowspan="1" colspan="1">1085 (6.7)</td><td align="left" rowspan="1" colspan="1">14773 (90.8)</td><td align="left" rowspan="1" colspan="1">16275</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 3 year, n (%)</td><td align="left" rowspan="1" colspan="1">1771 (64.9)</td><td align="left" rowspan="1" colspan="1">344 (12.6)</td><td align="left" rowspan="1" colspan="1">2115 (77.5)</td><td align="left" rowspan="1" colspan="1">2730</td><td align="left" rowspan="1" colspan="1">11119 (78.6)</td><td align="left" rowspan="1" colspan="1">1378 (9.7)</td><td align="left" rowspan="1" colspan="1">12497 (88.4)</td><td align="left" rowspan="1" colspan="1">14142</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 5 years, n (%)</td><td align="left" rowspan="1" colspan="1">1146 (55.6)</td><td align="left" rowspan="1" colspan="1">370 (17.9)</td><td align="left" rowspan="1" colspan="1">1516 (73.5)</td><td align="left" rowspan="1" colspan="1">2063</td><td align="left" rowspan="1" colspan="1">7224 (70.8)</td><td align="left" rowspan="1" colspan="1">1468 (14.4)</td><td align="left" rowspan="1" colspan="1">8692 (85.2)</td><td align="left" rowspan="1" colspan="1">10202</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Beta blocker</bold>
</td><td align="left" rowspan="1" colspan="1">4228</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20849</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prescribed, n (%)</td><td align="left" rowspan="1" colspan="1">3174 (75.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18490 (88.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary adherence</td><td align="left" rowspan="1" colspan="1">3030 (95.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">17838 (96.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 months, n (%)</td><td align="left" rowspan="1" colspan="1">2962 (99.3)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2962 (99.3)</td><td align="left" rowspan="1" colspan="1">2982</td><td align="left" rowspan="1" colspan="1">17427 (99.8)</td><td align="left" rowspan="1" colspan="1">3 (0)</td><td align="left" rowspan="1" colspan="1">17430 (99.8)</td><td align="left" rowspan="1" colspan="1">17458</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 6 months, n (%)</td><td align="left" rowspan="1" colspan="1">2419 (83.8)</td><td align="left" rowspan="1" colspan="1">66 (2.3)</td><td align="left" rowspan="1" colspan="1">2485 (86.0)</td><td align="left" rowspan="1" colspan="1">2888</td><td align="left" rowspan="1" colspan="1">15569 (92.5)</td><td align="left" rowspan="1" colspan="1">268 (1.6)</td><td align="left" rowspan="1" colspan="1">15837 (94.1)</td><td align="left" rowspan="1" colspan="1">16831</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 1 year, n (%)</td><td align="left" rowspan="1" colspan="1">2056 (74.5)</td><td align="left" rowspan="1" colspan="1">181 (6.6)</td><td align="left" rowspan="1" colspan="1">2237 (81.1)</td><td align="left" rowspan="1" colspan="1">2758</td><td align="left" rowspan="1" colspan="1">13569 (85.7)</td><td align="left" rowspan="1" colspan="1">846 (5.3)</td><td align="left" rowspan="1" colspan="1">14415 (91.1)</td><td align="left" rowspan="1" colspan="1">15827</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 year, n (%)</td><td align="left" rowspan="1" colspan="1">1638 (66.3)</td><td align="left" rowspan="1" colspan="1">271 (11.0)</td><td align="left" rowspan="1" colspan="1">1909 (77.3)</td><td align="left" rowspan="1" colspan="1">2470</td><td align="left" rowspan="1" colspan="1">10941 (77.9)</td><td align="left" rowspan="1" colspan="1">1418 (10.1)</td><td align="left" rowspan="1" colspan="1">12359 (88.0)</td><td align="left" rowspan="1" colspan="1">14044</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 3 year, n (%)</td><td align="left" rowspan="1" colspan="1">1324 (60.7)</td><td align="left" rowspan="1" colspan="1">288 (13.2)</td><td align="left" rowspan="1" colspan="1">1612 (73.9)</td><td align="left" rowspan="1" colspan="1">2182</td><td align="left" rowspan="1" colspan="1">8920 (72.8)</td><td align="left" rowspan="1" colspan="1">1594 (13.0)</td><td align="left" rowspan="1" colspan="1">10514 (85.8)</td><td align="left" rowspan="1" colspan="1">12250</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 5 years, n (%)</td><td align="left" rowspan="1" colspan="1">890 (53.5)</td><td align="left" rowspan="1" colspan="1">308 (18.5)</td><td align="left" rowspan="1" colspan="1">1198 (72.0)</td><td align="left" rowspan="1" colspan="1">1665</td><td align="left" rowspan="1" colspan="1">5853 (66.4)</td><td align="left" rowspan="1" colspan="1">1528 (17.3)</td><td align="left" rowspan="1" colspan="1">7381 (83.7)</td><td align="left" rowspan="1" colspan="1">8814</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ACEI/ARB</bold>
</td><td align="left" rowspan="1" colspan="1">3985</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20711</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prescribed, n (%)</td><td align="left" rowspan="1" colspan="1">2034 (51.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15085 (72.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary adherence</td><td align="left" rowspan="1" colspan="1">1935 (95.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14506 (96.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 months, n (%)</td><td align="left" rowspan="1" colspan="1">1909 (100)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1909 (100)</td><td align="left" rowspan="1" colspan="1">1909</td><td align="left" rowspan="1" colspan="1">14173 (88.0)</td><td align="left" rowspan="1" colspan="1">3 (0)</td><td align="left" rowspan="1" colspan="1">14176 (88.0)</td><td align="left" rowspan="1" colspan="1">16108</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">0.078</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 6 months, n (%)</td><td align="left" rowspan="1" colspan="1">1673 (90.3)</td><td align="left" rowspan="1" colspan="1">11 (0.6)</td><td align="left" rowspan="1" colspan="1">1684 (90.9)</td><td align="left" rowspan="1" colspan="1">1853</td><td align="left" rowspan="1" colspan="1">12879 (94.3)</td><td align="left" rowspan="1" colspan="1">(0.9)</td><td align="left" rowspan="1" colspan="1">12999 (95.2)</td><td align="left" rowspan="1" colspan="1">13659</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 1 year, n (%)</td><td align="left" rowspan="1" colspan="1">1450 (81.5)</td><td align="left" rowspan="1" colspan="1">42 (2.4)</td><td align="left" rowspan="1" colspan="1">1492 (83.8)</td><td align="left" rowspan="1" colspan="1">1780</td><td align="left" rowspan="1" colspan="1">11465 (89.1)</td><td align="left" rowspan="1" colspan="1">290 (2.3)</td><td align="left" rowspan="1" colspan="1">11755 (91.4)</td><td align="left" rowspan="1" colspan="1">12865</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 year, n (%)</td><td align="left" rowspan="1" colspan="1">1172 (76.8)</td><td align="left" rowspan="1" colspan="1">81 (5.3)</td><td align="left" rowspan="1" colspan="1">1180 (77.3)</td><td align="left" rowspan="1" colspan="1">1526</td><td align="left" rowspan="1" colspan="1">9538 (83.7)</td><td align="left" rowspan="1" colspan="1">509 (4.5)</td><td align="left" rowspan="1" colspan="1">10047 (88.1)</td><td align="left" rowspan="1" colspan="1">11399</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 3 year, n (%)</td><td align="left" rowspan="1" colspan="1">981 (70.1)</td><td align="left" rowspan="1" colspan="1">93 (6.6)</td><td align="left" rowspan="1" colspan="1">1074 (76.7)</td><td align="left" rowspan="1" colspan="1">1400</td><td align="left" rowspan="1" colspan="1">7880 (84.3)</td><td align="left" rowspan="1" colspan="1">592 (6.3)</td><td align="left" rowspan="1" colspan="1">7939 (84.9)</td><td align="left" rowspan="1" colspan="1">9352</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 5 years, n (%)</td><td align="left" rowspan="1" colspan="1">664 (63.6)</td><td align="left" rowspan="1" colspan="1">111 (10.6)</td><td align="left" rowspan="1" colspan="1">775 (74.2)</td><td align="left" rowspan="1" colspan="1">1044</td><td align="left" rowspan="1" colspan="1">5243 (74.2)</td><td align="left" rowspan="1" colspan="1">562 (8.0)</td><td align="left" rowspan="1" colspan="1">5805 (82.2)</td><td align="left" rowspan="1" colspan="1">7064</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>P2Y12-inhibitor</bold>
</td><td align="left" rowspan="1" colspan="1">5587</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">28882</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prescribed, n (%)</td><td align="left" rowspan="1" colspan="1">3746 (67.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">26003 (90.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary adherence</td><td align="left" rowspan="1" colspan="1">3535 (94.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25003 (96.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 2 months, n (%)</td><td align="left" rowspan="1" colspan="1">3478 (100)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3478 (100)</td><td align="left" rowspan="1" colspan="1">3479</td><td align="left" rowspan="1" colspan="1">24442 (100)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">24442 (100)</td><td align="left" rowspan="1" colspan="1">24443</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1">0.108</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 6 months, n (%)</td><td align="left" rowspan="1" colspan="1">1313 (38.8)</td><td align="left" rowspan="1" colspan="1">26 (0.8)</td><td align="left" rowspan="1" colspan="1">1339 (39.6)</td><td align="left" rowspan="1" colspan="1">3385</td><td align="left" rowspan="1" colspan="1">18110 (77.2)</td><td align="left" rowspan="1" colspan="1">168 (0.7)</td><td align="left" rowspan="1" colspan="1">18278 (77.9)</td><td align="left" rowspan="1" colspan="1">23465</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Persistens 1 year, n (%)</td><td align="left" rowspan="1" colspan="1">593 (18.4)</td><td align="left" rowspan="1" colspan="1">61 (1.9)</td><td align="left" rowspan="1" colspan="1">654 (20.3)</td><td align="left" rowspan="1" colspan="1">3219</td><td align="left" rowspan="1" colspan="1">12275 (55.8)</td><td align="left" rowspan="1" colspan="1">573 (2.6)</td><td align="left" rowspan="1" colspan="1">12848 (58.5)</td><td align="left" rowspan="1" colspan="1">21981</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="conclusions" id="sec019"><title>Discussion</title><p>This nationwide registry-based study investigated and compared the initiation, implementation and persistence rates of secondary preventive medications in patients with MINOCA and MI-CAD. Patients with MINOCA were less frequently prescribed secondary preventive medications at discharge, showed a lower rate of filling their first prescriptions, and had lower implementation and persistence rates than patients with MI-CAD.</p><p>The proportion of patients with high implementation decreased slowly over time, although &#x0003e;90% of patients in both groups initiated on aspirin, beta blockers, and ACEI/ARBs maintained a MPR&#x02009;&#x02265;&#x02009;80% during the entire follow-up period. The decreasing proportion of patients taking these medications over time is in agreement with several previous studies in patients with MI [<xref rid="pone.0324072.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0324072.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0324072.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0324072.ref012" ref-type="bibr">12</xref>]. A recent study of statin implementation among patients with atherosclerotic cardiovascular disease showed that only 21.4% had high implementation during the first year, decreasing to 19.8% at 3 years [<xref rid="pone.0324072.ref028" ref-type="bibr">28</xref>]. The different results between our study and this study may be due in part to different compositions of study cohorts and methodological differences in assessing implementation. The present study only measured implementation in patients who were persistent or labeled as users both at the beginning and the end of a time period, to avoid mix up non-implementation and non-persistence, whereas previous studies did not. Furthermore, implementation in the present study was calculated using shorter time intervals at the start of follow-up because change of medications, side effects, and subsequent discontinuation may be more frequent at the beginning of treatment.</p><p>The present study found that the persistence of aspirin and statins in patients with MINOCA was in agreement with the results of previous studies assessing the persistence in MI patients at 12&#x02013;18 months [<xref rid="pone.0324072.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0324072.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0324072.ref008" ref-type="bibr">8</xref>]. The rates of persistence of all medications throughout the entire follow-up period were higher in the present MI-CAD cohort than in previous studies [<xref rid="pone.0324072.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0324072.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0324072.ref008" ref-type="bibr">8</xref>]. The latter results are in agreement with a previous Swedish study investigating the long-term use of low-dose aspirin for both primary- and secondary prevention, with approximately 15% of those patients discontinuing long-term aspirin treatment after 3 years [<xref rid="pone.0324072.ref030" ref-type="bibr">30</xref>]. In contrast, the proportion of MINOCA patients in the present study who discontinued aspirin treatment was higher. However, the previous study found that patients who discontinued aspirin had a 37% higher rate of cardiovascular events after 3 years than those who were persistent [<xref rid="pone.0324072.ref030" ref-type="bibr">30</xref>]. The applicability of these findings to patients with MINOCA remains to be determined.</p><p>Several principal differences between patients with MINOCA and MI-CAD may affect the initiation, implementation, and persistence of secondary preventive medical treatment. First, the uncertainty of the diagnosis of MINOCA may affect both the attending physicians and patients&#x02019; willingness to prescribe medications and follow the prescription, respectively. The cause of MINOCA remains unclear in many patients [<xref rid="pone.0324072.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0324072.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0324072.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0324072.ref032" ref-type="bibr">32</xref>]. Thus, patients with MINOCA are less likely to be prescribed secondary preventive medications, less often undergo structured follow-up, and less frequently achieve secondary preventive targets than patients with MI-CAD [<xref rid="pone.0324072.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0324072.ref034" ref-type="bibr">34</xref>].</p><p>As recent guidelines recommend all patients with an initial working diagnosis of MINOCA follow a diagnostic algorithm, including a cardiac magnetic resonance (CMR) exam, to determine the underlying diagnosis [<xref rid="pone.0324072.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0324072.ref020" ref-type="bibr">20</xref>] the previously experienced uncertainty should decrease with time. Henceforth, a CMR exam with an ischemic late gadolinium enhancement pattern that strengthens the indication for secondary preventive medical treatment, as it carries a more serious prognosis than a non-ischemic pattern, may improve both the prescription of secondary preventive medications and follow-up [<xref rid="pone.0324072.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0324072.ref038" ref-type="bibr">38</xref>].</p><p>Second, the characteristics of patients with MINOCA differ from those with traditional MI. MINOCA patients tend to be younger, are more often women, and have fewer traditional risk factors for atherosclerotic heart disease [<xref rid="pone.0324072.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0324072.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0324072.ref039" ref-type="bibr">39</xref>]. Women with MI have been found to be less likely than men to receive evidence-based therapies and have lower referral rates for cardiac rehabilitation [<xref rid="pone.0324072.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0324072.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0324072.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0324072.ref041" ref-type="bibr">41</xref>]. Our subgroup analysis on women showed that the implementation of aspirin and statins were significantly higher in patients with MI-CAD than in those with MINOCA, whereas there was no difference in implementation rates of ACE/ARBs and beta blockers. Furthermore, persistence rates remained significantly higher in women with MI-CAD than in women with MINOCA, indicating that factors other than gender are important. Gender, however, may have a larger impact on the implementation and persistence of statins as perceived muscle symptoms associated with statin use are more common in women than in men [<xref rid="pone.0324072.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0324072.ref043" ref-type="bibr">43</xref>].</p><p>None of the MINOCA patients in the present study had undergone a coronary intervention. MI patients treated without PCI are less frequently prescribed secondary preventive drugs than patients who undergo PCI (7). Prior cardiovascular treatment has also been associated with high long-term implementation of secondary preventive treatment [<xref rid="pone.0324072.ref044" ref-type="bibr">44</xref>]. In contrast, patients with asymptomatic disease may be less adherent [<xref rid="pone.0324072.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0324072.ref045" ref-type="bibr">45</xref>].</p><p>Psychosocial factors may differ in patients with MINOCA and MI-CAD. Previous Swedish studies have indicated that pre-existing psychiatric disorders are more common in patients with MINOCA [<xref rid="pone.0324072.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0324072.ref047" ref-type="bibr">47</xref>]. Moreover, patients with MINOCA were found to have lower rates in the dimensions of vitality and mental health at 3 months follow-up than patients with MI-CAD [<xref rid="pone.0324072.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0324072.ref047" ref-type="bibr">47</xref>]. Other psychosocial factors, such as perceived social support and sense of coherence, have been associated with long-term adherence to secondary preventive measures in patients with MI [<xref rid="pone.0324072.ref048" ref-type="bibr">48</xref>]. Psychological belief and attitude are important in unintentional non-adherence, and beliefs about medication are important in intentional non-adherence [<xref rid="pone.0324072.ref049" ref-type="bibr">49</xref>].</p><p>A recent consensus document discussing adherence to secondary preventive therapy after cardiovascular diseases, recommended focus on all the five dimensions of adherence to therapy simultaneously; including the patient, the disease, the therapy, the healthcare provider and the healthcare system [<xref rid="pone.0324072.ref013" ref-type="bibr">13</xref>]. Thus, improving medical adherence requires both time and commitment. Novel interventions like digital health tools and follow-up programs that are both structured and individualized may contribute to an improvement of future secondary preventive medical treatment after both MINOCA and MI-CAD, but should preferably be studied in randomized trials.</p><sec id="sec020"><title>Strengths and limitations</title><p>This nationwide registry-based study included data from almost all patients hospitalized in Sweden for acute MI in 2006&#x02013;2017, allowing analyses of complete and unselected patient cohorts. These findings reflect real-life practice as opposed to the setting of randomized controlled trials, thereby increasing the generalizability of the results. The use of registry reduces potential selection bias associated with studies of patients at selected hospitals or enrolled in health care insurance systems. Furthermore, restricting the assessment of implementation and persistence only to patients who had a de novo prescription for each indicated class of drugs reduced the influence of on-going prescriptions on long-term persistence.</p><p>However, this registry-based analysis had several limitations. The analysis relied on ICD-codes and the possibility of coding errors cannot be ruled out. Diagnostic criteria for MINOCA were not proposed until 2017 [<xref rid="pone.0324072.ref019" ref-type="bibr">19</xref>], making it impossible to determine how many patients, who today would meet the criteria for MINOCA, were diagnosed with a non-MI related condition. Furthermore, CMR imaging was not used to the same extent during the study period as today and it is possible some of the patients labelled as MINOCA in this study in fact had an undiagnosed Takotsubo cardiomyopathy or myocarditis [<xref rid="pone.0324072.ref035" ref-type="bibr">35</xref>].</p><p>The secondary preventive medication after MI recommended in guidelines have been similar during the study period, e.g., class 1 recommendations for aspirin, beta blockers, ACEI/ARB and statins [<xref rid="pone.0324072.ref050" ref-type="bibr">50</xref>], whereas recommendations specific for MINOCA weren&#x02019;t published until after the study period [<xref rid="pone.0324072.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0324072.ref020" ref-type="bibr">20</xref>]. The physician&#x02019;s prescription pattern of secondary preventive medications to patients with MINOCA may therefore vary over time. However, to minimize the impact of the prescription patterns the present study only included patients prescribed and initiating medication in further analyses of implementation and persistence.</p><p>The Swedish Prescribed Drug Register records complete data of prescribed drugs dispensed to individuals. However, it do not contain information how many patients who were prescribed drugs did not collect them or the number of those collecting the drugs who did not take them.</p><p>In addition, the lack of information on patient socioeconomic status and previous psychiatric illnesses may have resulted in residual confounding, as factors such as low economic status, low education status and psychiatric disease are previously described barriers to adherence to treatment [<xref rid="pone.0324072.ref013" ref-type="bibr">13</xref>].</p><p>The differences between this study and previous studies in the methods used to measure implementation and persistence make it difficult to compare results. Compared with many previous studies, the present study applied a stricter initial definition, measuring implementation and persistence only in patients with primary adherence to treatment, but a less rigid follow-up approach including patients who restarted treatment in the user group. Both of these factors may have resulted in higher levels of persistence at later time points than observed with other approaches, but may better reflect real world conditions.</p></sec></sec><sec sec-type="conclusions" id="sec021"><title>Conclusions</title><p>This nationwide study demonstrated that the rates of initiation, implementation, and persistence of secondary preventive medications were high in both MINOCA and MI-CAD patients during the first 5 years after MI. These rates, however, were lower in patients with MINOCA, a difference that may be partially due to uncertainties regarding the diagnosis of MINOCA, differences in patient characteristics, and psychosocial factors. Suboptimal medical adherence in patients with MINOCA may adversely affect prognosis as previously demonstrated in MI-CAD patients.</p></sec><sec id="sec022" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0324072.s001" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Adherence to medication.</title><p>On the first day of each interval, the proportion of persistent patients was calculated by dividing the number of persistent patients by the number of patients remaining in the cohort. Only patients with a de novo prescription of a drug class were included in analysis of that drug class. Patients with ongoing treatment or a prescription 6 months prior to myocardial infarction were excluded from analysis of that drug class.</p><p>(DOCX)</p></caption><media xlink:href="pone.0324072.s001.docx"/></supplementary-material><supplementary-material id="pone.0324072.s002" position="float" content-type="local-data"><label>S2 Table</label><caption><title>Implementation of secondary preventive treatment with aspirin, statins, ACEI/ARBs, and beta blockers in patients with MINOCA and MI-CAD.</title><p>Medication possession ratio (MPR) &#x02265;80% was defined as high adherence.</p><p>(DOCX)</p></caption><media xlink:href="pone.0324072.s002.docx"/></supplementary-material></sec></body><back><ack><p>We thank Karin Jensevik Eriksson, MSc, Biostatistician, for assistance with the compilation of data into the database.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>ACEI</term><def><p>angiotensin-converting enzyme inhibitor</p></def></def-item><def-item><term>ARB</term><def><p>angiotensin-receptor blocker</p></def></def-item><def-item><term>MI-CAD</term><def><p>myocardial infarction with obstructive coronary arteries</p></def></def-item><def-item><term>MINOCA</term><def><p>myocardial infarction with non-obstructive coronary arteries.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0324072.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Amsterdam</surname><given-names>EA</given-names></name>, <name><surname>Wenger</surname><given-names>NK</given-names></name>, <name><surname>Brindis</surname><given-names>RG</given-names></name>, <name><surname>Casey DE</surname><given-names>Jr</given-names></name>, <name><surname>Ganiats</surname><given-names>TG</given-names></name>, <name><surname>Holmes DR</surname><given-names>Jr</given-names></name>, <etal>et al</etal>. <article-title>2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>130</volume>(<issue>25</issue>):<fpage>2354</fpage>&#x02013;<lpage>94</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIR.0000000000000133</pub-id>
<pub-id pub-id-type="pmid">25249586</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Collet</surname><given-names>J-P</given-names></name>, <name><surname>Thiele</surname><given-names>H</given-names></name>, <name><surname>Barbato</surname><given-names>E</given-names></name>, <name><surname>Barth&#x000e9;l&#x000e9;my</surname><given-names>O</given-names></name>, <name><surname>Bauersachs</surname><given-names>J</given-names></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <etal>et al</etal>. <article-title>2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation</article-title>. <source>Eur Heart J</source>. <year>2021</year>;<volume>42</volume>(<issue>14</issue>):<fpage>1289</fpage>&#x02013;<lpage>367</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa575</pub-id>
<pub-id pub-id-type="pmid">32860058</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Ibanez</surname><given-names>B</given-names></name>, <name><surname>James</surname><given-names>S</given-names></name>, <name><surname>Agewall</surname><given-names>S</given-names></name>, <name><surname>Antunes</surname><given-names>MJ</given-names></name>, <name><surname>Bucciarelli-Ducci</surname><given-names>C</given-names></name>, <name><surname>Bueno</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source>. <year>2018</year>;<volume>39</volume>(<issue>2</issue>):<fpage>119</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id>
<pub-id pub-id-type="pmid">28886621</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Bansilal</surname><given-names>S</given-names></name>, <name><surname>Castellano</surname><given-names>JM</given-names></name>, <name><surname>Garrido</surname><given-names>E</given-names></name>, <name><surname>Wei</surname><given-names>HG</given-names></name>, <name><surname>Freeman</surname><given-names>A</given-names></name>, <name><surname>Spettell</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Assessing the impact of medication adherence on long-term cardiovascular outcomes</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>68</volume>(<issue>8</issue>):<fpage>789</fpage>&#x02013;<lpage>801</lpage>.<pub-id pub-id-type="pmid">27539170</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Eindhoven</surname><given-names>DC</given-names></name>, <name><surname>Hilt</surname><given-names>AD</given-names></name>, <name><surname>Zwaan</surname><given-names>TC</given-names></name>, <name><surname>Schalij</surname><given-names>MJ</given-names></name>, <name><surname>Borleffs</surname><given-names>CJW</given-names></name>. <article-title>Age and gender differences in medical adherence after myocardial infarction: women do not receive optimal treatment - The Netherlands claims database</article-title>. <source>Eur J Prev Cardiol</source>. <year>2018</year>;<volume>25</volume>(<issue>2</issue>):<fpage>181</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/2047487317744363</pub-id>
<pub-id pub-id-type="pmid">29164916</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Greenland</surname><given-names>M</given-names></name>, <name><surname>Knuiman</surname><given-names>MW</given-names></name>, <name><surname>Hung</surname><given-names>J</given-names></name>, <name><surname>Nedkoff</surname><given-names>L</given-names></name>, <name><surname>Arnet</surname><given-names>I</given-names></name>, <name><surname>Rankin</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>4315</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-60799-5</pub-id>
<pub-id pub-id-type="pmid">32152400</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Halvorsen</surname><given-names>S</given-names></name>, <name><surname>Jortveit</surname><given-names>J</given-names></name>, <name><surname>Hasvold</surname><given-names>P</given-names></name>, <name><surname>Thuresson</surname><given-names>M</given-names></name>, <name><surname>&#x000d8;ie</surname><given-names>E</given-names></name>. <article-title>Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2016</year>;<volume>16</volume>:<fpage>115</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12872-016-0283-6</pub-id>
<pub-id pub-id-type="pmid">27246583</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Hambraeus</surname><given-names>K</given-names></name>, <name><surname>Tyd&#x000e9;n</surname><given-names>P</given-names></name>, <name><surname>Lindahl</surname><given-names>B</given-names></name>. <article-title>Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: data from the SWEDEHEART registry</article-title>. <source>Eur J Prev Cardiol</source>. <year>2016</year>;<volume>23</volume>(<issue>4</issue>):<fpage>340</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/2047487315585293</pub-id>
<pub-id pub-id-type="pmid">25986497</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Khalaf</surname><given-names>K</given-names></name>, <name><surname>Johnell</surname><given-names>K</given-names></name>, <name><surname>Austin</surname><given-names>PC</given-names></name>, <name><surname>Tyden</surname><given-names>P</given-names></name>, <name><surname>Midl&#x000f6;v</surname><given-names>P</given-names></name>, <name><surname>Perez-Vicente</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk-an inverse probability of treatment weighted study on 54&#x02009;872 patients</article-title>. <source>Eur Heart J Cardiovasc Pharmacother</source>. <year>2021</year>;<volume>7</volume>(<issue>2</issue>):<fpage>141</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ehjcvp/pvaa010</pub-id>
<pub-id pub-id-type="pmid">32058542</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Khan</surname><given-names>R</given-names></name>, <name><surname>Kaul</surname><given-names>P</given-names></name>, <name><surname>Islam</surname><given-names>S</given-names></name>, <name><surname>Savu</surname><given-names>A</given-names></name>, <name><surname>Bagai</surname><given-names>A</given-names></name>, <name><surname>van Diepen</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Drug adherence and long-term outcomes in non-revascularized patients following acute myocardial infarction</article-title>. <source>Am J Cardiol</source>. <year>2021</year>;<volume>152</volume>:<fpage>49</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.amjcard.2021.04.031</pub-id>
<pub-id pub-id-type="pmid">34120704</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Rodriguez</surname><given-names>F</given-names></name>, <name><surname>Maron</surname><given-names>DJ</given-names></name>, <name><surname>Knowles</surname><given-names>JW</given-names></name>, <name><surname>Virani</surname><given-names>SS</given-names></name>, <name><surname>Lin</surname><given-names>S</given-names></name>, <name><surname>Heidenreich</surname><given-names>PA</given-names></name>. <article-title>Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease</article-title>. <source>JAMA Cardiol</source>. <year>2019</year>;<volume>4</volume>(<issue>3</issue>):<fpage>206</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jamacardio.2018.4936</pub-id>
<pub-id pub-id-type="pmid">30758506</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Shang</surname><given-names>P</given-names></name>, <name><surname>Liu</surname><given-names>GG</given-names></name>, <name><surname>Zheng</surname><given-names>X</given-names></name>, <name><surname>Ho</surname><given-names>PM</given-names></name>, <name><surname>Hu</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Association between medication adherence and 1-year major cardiovascular adverse events after acute myocardial infarction in China</article-title>. <source>J Am Heart Assoc</source>. <year>2019</year>;<volume>8</volume>(<issue>9</issue>):e011793. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/JAHA.118.011793</pub-id>
<pub-id pub-id-type="pmid">31057004</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Pedretti</surname><given-names>RFE</given-names></name>, <name><surname>Hansen</surname><given-names>D</given-names></name>, <name><surname>Ambrosetti</surname><given-names>M</given-names></name>, <name><surname>Back</surname><given-names>M</given-names></name>, <name><surname>Berger</surname><given-names>T</given-names></name>, <name><surname>Ferreira</surname><given-names>MC</given-names></name>, <etal>et al</etal>. <article-title>How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology</article-title>. <source>Eur J Prev Cardiol</source>. <year>2023</year>;<volume>30</volume>(<issue>2</issue>):<fpage>149</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">36098041</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Nordenskj&#x000f6;ld</surname><given-names>AM</given-names></name>, <name><surname>Baron</surname><given-names>T</given-names></name>, <name><surname>Eggers</surname><given-names>KM</given-names></name>, <name><surname>Jernberg</surname><given-names>T</given-names></name>, <name><surname>Lindahl</surname><given-names>B</given-names></name>. <article-title>Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease</article-title>. <source>Int J Cardiol</source>. <year>2018</year>;<volume>261</volume>:<fpage>18</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijcard.2018.03.056</pub-id>
<pub-id pub-id-type="pmid">29563017</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Pasupathy</surname><given-names>S</given-names></name>, <name><surname>Lindahl</surname><given-names>B</given-names></name>, <name><surname>Litwin</surname><given-names>P</given-names></name>, <name><surname>Tavella</surname><given-names>R</given-names></name>, <name><surname>Williams</surname><given-names>MJA</given-names></name>, <name><surname>Air</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Survival in patients with suspected myocardial infarction with nonobstructive coronary arteries: a comprehensive systematic review and meta-analysis from the MINOCA Global Collaboration</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2021</year>;<volume>14</volume>(<issue>11</issue>):e007880. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.121.007880</pub-id>
<pub-id pub-id-type="pmid">34784229</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Brecker</surname><given-names>SJ</given-names></name>. <article-title>Myocardial infarction in patients with normal coronary arteries</article-title>. <source>Ann Med</source>. <year>1994</year>;<volume>26</volume>(<issue>6</issue>):<fpage>383</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3109/07853899409148356</pub-id>
<pub-id pub-id-type="pmid">7695860</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>DeWood</surname><given-names>MA</given-names></name>, <name><surname>Spores</surname><given-names>J</given-names></name>, <name><surname>Notske</surname><given-names>R</given-names></name>, <name><surname>Mouser</surname><given-names>LT</given-names></name>, <name><surname>Burroughs</surname><given-names>R</given-names></name>, <name><surname>Golden</surname><given-names>MS</given-names></name>, <etal>et al</etal>. <article-title>Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1980</year>;<volume>303</volume>(<issue>16</issue>):<fpage>897</fpage>&#x02013;<lpage>902</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJM198010163031601</pub-id>
<pub-id pub-id-type="pmid">7412821</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>DeWood</surname><given-names>MA</given-names></name>, <name><surname>Stifter</surname><given-names>WF</given-names></name>, <name><surname>Simpson</surname><given-names>CS</given-names></name>, <name><surname>Spores</surname><given-names>J</given-names></name>, <name><surname>Eugster</surname><given-names>GS</given-names></name>, <name><surname>Judge</surname><given-names>TP</given-names></name>, <etal>et al</etal>. <article-title>Coronary arteriographic findings soon after non-Q-wave myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1986</year>;<volume>315</volume>(<issue>7</issue>):<fpage>417</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJM198608143150703</pub-id>
<pub-id pub-id-type="pmid">3736619</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Agewall</surname><given-names>S</given-names></name>, <name><surname>Beltrame</surname><given-names>JF</given-names></name>, <name><surname>Reynolds</surname><given-names>HR</given-names></name>, <name><surname>Niessner</surname><given-names>A</given-names></name>, <name><surname>Rosano</surname><given-names>G</given-names></name>, <name><surname>Caforio</surname><given-names>ALP</given-names></name>, <etal>et al</etal>. <article-title>ESC working group position paper on myocardial infarction with non-obstructive coronary arteries</article-title>. <source>Eur Heart J</source>. <year>2017</year>;<volume>38</volume>(<issue>3</issue>):<fpage>143</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/eurheartj/ehw149</pub-id>
<pub-id pub-id-type="pmid">28158518</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Tamis-Holland</surname><given-names>J</given-names></name>, <name><surname>Jneid</surname><given-names>H</given-names></name>, <name><surname>Reynolds</surname><given-names>H</given-names></name>, <name><surname>Agewall</surname><given-names>S</given-names></name>, <name><surname>Brilakis</surname><given-names>E</given-names></name>, <name><surname>Brown</surname><given-names>T</given-names></name>. <article-title>Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>139</volume>(<issue>18</issue>):e891&#x02013;<lpage>908</lpage>.</mixed-citation></ref><ref id="pone.0324072.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Eggers</surname><given-names>KM</given-names></name>, <name><surname>Hadziosmanovi</surname><given-names>N</given-names></name>, <name><surname>Baron</surname><given-names>T</given-names></name>, <name><surname>Hambraeus</surname><given-names>K</given-names></name>, <name><surname>Jernberg</surname><given-names>T</given-names></name>, <name><surname>Nordenskjold</surname><given-names>AM</given-names></name>. <article-title>Myocardial infarction with nonobstructive coronary arteries: the importance of achieving secondary prevention targets</article-title>. <source>Am J Med</source>. <year>2018</year>;<volume>131</volume>(<issue>5</issue>):524-531.e6.</mixed-citation></ref><ref id="pone.0324072.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Paolisso</surname><given-names>P</given-names></name>, <name><surname>Bergamaschi</surname><given-names>L</given-names></name>, <name><surname>Saturi</surname><given-names>G</given-names></name>, <name><surname>D&#x02019;Angelo</surname><given-names>EC</given-names></name>, <name><surname>Magnani</surname><given-names>I</given-names></name>, <name><surname>Toniolo</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Secondary prevention medical therapy and outcomes in patients with myocardial infarction with non-obstructive coronary artery disease</article-title>. <source>Front Pharmacol</source>. <year>2020</year>;<volume>10</volume>:<fpage>1606</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphar.2019.01606</pub-id>
<pub-id pub-id-type="pmid">32082147</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Jernberg</surname><given-names>T</given-names></name>, <name><surname>Attebring</surname><given-names>MF</given-names></name>, <name><surname>Hambraeus</surname><given-names>K</given-names></name>, <name><surname>Ivert</surname><given-names>T</given-names></name>, <name><surname>James</surname><given-names>S</given-names></name>, <name><surname>Jeppsson</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)</article-title>. <source>Heart</source>. <year>2010</year>;<volume>96</volume>(<issue>20</issue>):<fpage>1617</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/hrt.2010.198804</pub-id>
<pub-id pub-id-type="pmid">20801780</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Ludvigsson</surname><given-names>JF</given-names></name>, <name><surname>Andersson</surname><given-names>E</given-names></name>, <name><surname>Ekbom</surname><given-names>A</given-names></name>, <name><surname>Feychting</surname><given-names>M</given-names></name>, <name><surname>Kim</surname><given-names>J-L</given-names></name>, <name><surname>Reuterwall</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>External review and validation of the Swedish national inpatient register</article-title>. <source>BMC Public Health</source>. <year>2011</year>;<volume>11</volume>:<fpage>450</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2458-11-450</pub-id>
<pub-id pub-id-type="pmid">21658213</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Wettermark</surname><given-names>B</given-names></name>, <name><surname>Hammar</surname><given-names>N</given-names></name>, <name><surname>Fored</surname><given-names>CM</given-names></name>, <name><surname>Leimanis</surname><given-names>A</given-names></name>, <name><surname>Otterblad Olausson</surname><given-names>P</given-names></name>, <name><surname>Bergman</surname><given-names>U</given-names></name>, <etal>et al</etal>. <article-title>The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2007</year>;<volume>16</volume>(<issue>7</issue>):<fpage>726</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/pds.1294</pub-id>
<pub-id pub-id-type="pmid">16897791</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Vink</surname><given-names>NM</given-names></name>, <name><surname>Klungel</surname><given-names>OH</given-names></name>, <name><surname>Stolk</surname><given-names>RP</given-names></name>, <name><surname>Denig</surname><given-names>P</given-names></name>. <article-title>Comparison of various measures for assessing medication refill adherence using prescription data</article-title>. <source>Pharmacoepidemiol Drug Saf</source>. <year>2009</year>;<volume>18</volume>(<issue>2</issue>):<fpage>159</fpage>&#x02013;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/pds.1698</pub-id>
<pub-id pub-id-type="pmid">19109809</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Parker</surname><given-names>MM</given-names></name>, <name><surname>Moffet</surname><given-names>HH</given-names></name>, <name><surname>Adams</surname><given-names>A</given-names></name>, <name><surname>Karter</surname><given-names>AJ</given-names></name>. <article-title>An algorithm to identify medication nonpersistence using electronic pharmacy databases</article-title>. <source>J Am Med Inform Assoc</source>. <year>2015</year>;<volume>22</volume>(<issue>5</issue>):<fpage>957</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jamia/ocv054</pub-id>
<pub-id pub-id-type="pmid">26078413</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>May</surname><given-names>HT</given-names></name>, <name><surname>Knowlton</surname><given-names>KU</given-names></name>, <name><surname>Anderson</surname><given-names>JL</given-names></name>, <name><surname>Lapp&#x000e9;</surname><given-names>DL</given-names></name>, <name><surname>Bair</surname><given-names>TL</given-names></name>, <name><surname>Muhlestein</surname><given-names>JB</given-names></name>. <article-title>High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study</article-title>. <source>Eur Heart J Qual Care Clin Outcomes</source>. <year>2022</year>;<volume>8</volume>(<issue>3</issue>):<fpage>352</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ehjqcco/qcab024</pub-id>
<pub-id pub-id-type="pmid">33787865</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Baumgartner</surname><given-names>PC</given-names></name>, <name><surname>Haynes</surname><given-names>RB</given-names></name>, <name><surname>Hersberger</surname><given-names>KE</given-names></name>, <name><surname>Arnet</surname><given-names>I</given-names></name>. <article-title>A systematic review of medication adherence thresholds dependent of clinical outcomes</article-title>. <source>Front Pharmacol</source>. <year>2018</year>;<volume>9</volume>:<fpage>1290</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphar.2018.01290</pub-id>
<pub-id pub-id-type="pmid">30524276</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Sundstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Hedberg</surname><given-names>J</given-names></name>, <name><surname>Thuresson</surname><given-names>M</given-names></name>, <name><surname>Aarskog</surname><given-names>P</given-names></name>, <name><surname>Johannesen</surname><given-names>KM</given-names></name>, <name><surname>Oldgren</surname><given-names>J</given-names></name>. <article-title>Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish Nationwide, Population-Based Cohort Study</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>136</volume>(<issue>13</issue>):<fpage>1183</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.028321</pub-id>
<pub-id pub-id-type="pmid">28947478</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Machanahalli</surname><given-names>A</given-names></name>, <name><surname>Balakrishna</surname><given-names>A</given-names></name>, <name><surname>Ismayl</surname><given-names>M</given-names></name>, <name><surname>Thandra</surname><given-names>A</given-names></name>, <name><surname>Walters</surname><given-names>R</given-names></name>, <name><surname>Ganesan</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Diagnostic value of cardiac magnetic resonance imaging and intracoronary optical coherence tomography in patients with a working diagnosis of myocardial infarction with non-obstructive coronary arteries - a systematic review and meta-analysis</article-title>. <source>Curr Probl Cardiol</source>. <year>2022</year>;<volume>2022</volume>:<fpage>101126</fpage>.</mixed-citation></ref><ref id="pone.0324072.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>S&#x000f6;rensson</surname><given-names>P</given-names></name>, <name><surname>Ekenb&#x000e4;ck</surname><given-names>C</given-names></name>, <name><surname>Lundin</surname><given-names>M</given-names></name>, <name><surname>Agewall</surname><given-names>S</given-names></name>, <name><surname>Bacsovics Brolin</surname><given-names>E</given-names></name>, <name><surname>Caidahl</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Early comprehensive cardiovascular magnetic resonance imaging in patients with myocardial infarction with nonobstructive coronary arteries</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2021</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1774</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jcmg.2021.02.021</pub-id>
<pub-id pub-id-type="pmid">33865778</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Eggers</surname><given-names>KM</given-names></name>, <name><surname>Hadziosmanovic</surname><given-names>N</given-names></name>, <name><surname>Baron</surname><given-names>T</given-names></name>, <name><surname>Hambraeus</surname><given-names>K</given-names></name>, <name><surname>Jernberg</surname><given-names>T</given-names></name>, <name><surname>Nordenskjold</surname><given-names>A</given-names></name>. <article-title>Myocardial infarction with nonobstructive coronary arteries: the importance of achieving secondary prevention targets</article-title>. <source>Am J Med</source>. <year>2018</year>;<volume>131</volume>(<issue>5</issue>):524-31 e6.</mixed-citation></ref><ref id="pone.0324072.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Sharaf</surname><given-names>B</given-names></name>, <name><surname>Wood</surname><given-names>T</given-names></name>, <name><surname>Shaw</surname><given-names>L</given-names></name>, <name><surname>Johnson</surname><given-names>BD</given-names></name>, <name><surname>Kelsey</surname><given-names>S</given-names></name>, <name><surname>Anderson</surname><given-names>RD</given-names></name>, <etal>et al</etal>. <article-title>Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women&#x02019;s Ischemia Syndrome Evaluation (WISE) angiographic core laboratory</article-title>. <source>Am Heart J</source>. <year>2013</year>;<volume>166</volume>(<issue>1</issue>):<fpage>134</fpage>&#x02013;<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ahj.2013.04.002</pub-id>
<pub-id pub-id-type="pmid">23816032</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Bucciarelli</surname><given-names>V</given-names></name>, <name><surname>Bianco</surname><given-names>F</given-names></name>, <name><surname>Di Francesco</surname><given-names>A</given-names></name>, <name><surname>Vitulli</surname><given-names>P</given-names></name>, <name><surname>Biasi</surname><given-names>A</given-names></name>, <name><surname>Primavera</surname><given-names>M</given-names></name>. <article-title>Characteristics and prognosis of a contemporary cohort with myocardial infarction with non-obstructed coronary arteries (MINOCA) presenting different patterns of late gadolinium enhancements in cardiac magnetic resonance imaging</article-title>. <source>J Clin Med</source>. <year>2023</year>;<volume>12</volume>(<issue>2266</issue>).</mixed-citation></ref><ref id="pone.0324072.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Ciliberti</surname><given-names>G</given-names></name>, <name><surname>Verdoia</surname><given-names>M</given-names></name>, <name><surname>Merlo</surname><given-names>M</given-names></name>, <name><surname>Zilio</surname><given-names>F</given-names></name>, <name><surname>Vatrano</surname><given-names>M</given-names></name>, <name><surname>Bianco</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Pharmacological therapy for the prevention of cardiovascular events in patients with myocardial infarction with non-obstructed coronary arteries (MINOCA): Insights from a multicentre national registry</article-title>. <source>Int J Cardiol</source>. <year>2021</year>;<volume>327</volume>:<fpage>9</fpage>&#x02013;<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijcard.2020.11.040</pub-id>
<pub-id pub-id-type="pmid">33242505</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref037"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Bergamaschi</surname><given-names>L</given-names></name>, <name><surname>Fo&#x000e0;</surname><given-names>A</given-names></name>, <name><surname>Paolisso</surname><given-names>P</given-names></name>, <name><surname>Renzulli</surname><given-names>M</given-names></name>, <name><surname>Angeli</surname><given-names>F</given-names></name>, <name><surname>Fabrizio</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Prognostic role of early cardiac magnetic resonance in myocardial infarction with nonobstructive coronary arteries.</article-title>
<source>JACC Cardiovasc Imaging</source>. <year>2024</year>;<volume>17</volume>(<issue>2</issue>):<fpage>149</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">37480903</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref038"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Dastidar</surname><given-names>AG</given-names></name>, <name><surname>Baritussio</surname><given-names>A</given-names></name>, <name><surname>De Garate</surname><given-names>E</given-names></name>, <name><surname>Drobni</surname><given-names>Z</given-names></name>, <name><surname>Biglino</surname><given-names>G</given-names></name>, <name><surname>Singhal</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Prognostic role of CMR and conventional risk factors in myocardial infarction with nonobstructed coronary arteries.</article-title>
<source>JACC Cardiovasc Imaging</source>. <year>2019</year>;<volume>12</volume>(<issue>10</issue>):<fpage>1973</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">30772224</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Lindahl</surname><given-names>B</given-names></name>, <name><surname>Baron</surname><given-names>T</given-names></name>, <name><surname>Erlinge</surname><given-names>D</given-names></name>, <name><surname>Hadziosmanovic</surname><given-names>N</given-names></name>, <name><surname>Nordenskj&#x000f6;ld</surname><given-names>A</given-names></name>, <name><surname>Gard</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>135</volume>(<issue>16</issue>):<fpage>1481</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.026336</pub-id>
<pub-id pub-id-type="pmid">28179398</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Chandrasekhar</surname><given-names>J</given-names></name>, <name><surname>Gill</surname><given-names>A</given-names></name>, <name><surname>Mehran</surname><given-names>R</given-names></name>. <article-title>Acute myocardial infarction in young women: current perspectives</article-title>. <source>Int J Womens Health</source>. <year>2018</year>;<volume>10</volume>:<fpage>267</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/IJWH.S107371</pub-id>
<pub-id pub-id-type="pmid">29922097</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Hyun</surname><given-names>K</given-names></name>, <name><surname>Negrone</surname><given-names>A</given-names></name>, <name><surname>Redfern</surname><given-names>J</given-names></name>, <name><surname>Atkins</surname><given-names>E</given-names></name>, <name><surname>Chow</surname><given-names>C</given-names></name>, <name><surname>Kilian</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Gender difference in secondary prevention of cardiovascular disease and outcomes following the survival of acute coronary syndrome</article-title>. <source>Heart Lung Circ</source>. <year>2021</year>;<volume>30</volume>(<issue>1</issue>):<fpage>121</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.hlc.2020.06.026</pub-id>
<pub-id pub-id-type="pmid">32888821</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Karalis</surname><given-names>DG</given-names></name>, <name><surname>Wild</surname><given-names>RA</given-names></name>, <name><surname>Maki</surname><given-names>KC</given-names></name>, <name><surname>Gaskins</surname><given-names>R</given-names></name>, <name><surname>Jacobson</surname><given-names>TA</given-names></name>, <name><surname>Sponseller</surname><given-names>CA</given-names></name>, <etal>et al</etal>. <article-title>Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study</article-title>. <source>J Clin Lipidol</source>. <year>2016</year>;<volume>10</volume>(<issue>4</issue>):<fpage>833</fpage>&#x02013;<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jacl.2016.02.016</pub-id>
<pub-id pub-id-type="pmid">27578114</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Ruscica</surname><given-names>M</given-names></name>, <name><surname>Ferri</surname><given-names>N</given-names></name>, <name><surname>Banach</surname><given-names>M</given-names></name>, <name><surname>Sirtori</surname><given-names>C</given-names></name>, <name><surname>Corsini</surname><given-names>A</given-names></name>. <article-title>Side effects of statins from pathophysiology and epidemiology to diagnostic and therapeutic implications</article-title>. <source>Cardiovasc Res</source>. <year>2022</year>.</mixed-citation></ref><ref id="pone.0324072.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Campain</surname><given-names>A</given-names></name>, <name><surname>Hockham</surname><given-names>C</given-names></name>, <name><surname>Sukkar</surname><given-names>L</given-names></name>, <name><surname>Rogers</surname><given-names>K</given-names></name>, <name><surname>Chow</surname><given-names>C</given-names></name>, <name><surname>Lung</surname><given-names>T</given-names></name>. <article-title>Prior cardiovascular treatments-a key characteristic in determining medication adherence after an acute myocardial infarction</article-title>. <source>Front Pharmacol</source>. <year>2022</year>;<volume>13</volume>:<fpage>834898</fpage>.<pub-id pub-id-type="pmid">35330840</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Sewitch</surname><given-names>MJ</given-names></name>, <name><surname>Abrahamowicz</surname><given-names>M</given-names></name>, <name><surname>Barkun</surname><given-names>A</given-names></name>, <name><surname>Bitton</surname><given-names>A</given-names></name>, <name><surname>Wild</surname><given-names>GE</given-names></name>, <name><surname>Cohen</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Patient nonadherence to medication in inflammatory bowel disease</article-title>. <source>Am J Gastroenterol</source>. <year>2003</year>;<volume>98</volume>(<issue>7</issue>):<fpage>1535</fpage>&#x02013;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07522.x</pub-id>
<pub-id pub-id-type="pmid">12873575</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Daniel</surname><given-names>M</given-names></name>, <name><surname>Agewall</surname><given-names>S</given-names></name>, <name><surname>Berglund</surname><given-names>F</given-names></name>, <name><surname>Caidahl</surname><given-names>K</given-names></name>, <name><surname>Collste</surname><given-names>O</given-names></name>, <name><surname>Ekenb&#x000e4;ck</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Prevalence of anxiety and depression symptoms in patients with myocardial infarction with non-obstructive coronary arteries</article-title>. <source>Am J Med</source>. <year>2018</year>;<volume>131</volume>(<issue>9</issue>):<fpage>1118</fpage>&#x02013;<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.amjmed.2018.04.040</pub-id>
<pub-id pub-id-type="pmid">29859805</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Daniel</surname><given-names>M</given-names></name>, <name><surname>Agewall</surname><given-names>S</given-names></name>, <name><surname>Caidahl</surname><given-names>K</given-names></name>, <name><surname>Collste</surname><given-names>O</given-names></name>, <name><surname>Ekenb&#x000e4;ck</surname><given-names>C</given-names></name>, <name><surname>Frick</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Effect of myocardial infarction with nonobstructive coronary arteries on physical capacity and quality-of-life</article-title>. <source>Am J Cardiol</source>. <year>2017</year>;<volume>120</volume>(<issue>3</issue>):<fpage>341</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.amjcard.2017.05.001</pub-id>
<pub-id pub-id-type="pmid">28610801</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Nachshol</surname><given-names>M</given-names></name>, <name><surname>Lurie</surname><given-names>I</given-names></name>, <name><surname>Benyamini</surname><given-names>Y</given-names></name>, <name><surname>Goldbourt</surname><given-names>U</given-names></name>, <name><surname>Gerber</surname><given-names>Y</given-names></name>. <article-title>Role of psychosocial factors in long-term adherence to secondary prevention measures after myocardial infarction: a longitudinal analysis</article-title>. <source>Ann Epidemiol</source>. <year>2020</year>;<volume>52</volume>:<fpage>35</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">33031935</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>Y</given-names></name>, <name><surname>Park</surname><given-names>Y-H</given-names></name>, <name><surname>Park</surname><given-names>K-S</given-names></name>. <article-title>Determinants of non-adherences to long-term medical therapy after myocardial infarction: a cross-sectional study</article-title>. <source>Int J Environ Res Public Health</source>. <year>2020</year>;<volume>17</volume>(<issue>10</issue>):<fpage>3585</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijerph17103585</pub-id>
<pub-id pub-id-type="pmid">32443775</pub-id>
</mixed-citation></ref><ref id="pone.0324072.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>J</given-names></name>, <name><surname>Adams</surname><given-names>C</given-names></name>, <name><surname>Antman</surname><given-names>E</given-names></name>, <name><surname>Bridges</surname><given-names>C</given-names></name>, <name><surname>Califf</surname><given-names>R</given-names></name>, <name><surname>Casey</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>(<issue>7</issue>):e1&#x02013;<lpage>157</lpage>.</mixed-citation></ref></ref-list></back></article>